574745-97-4

Basic information

• Product Name: 4-Chloro-6-hydroxy-7-meth...
• Synonyms: 4-Chloro-6-hydroxy-7-meth...;4-Chloro-6-hydroxy-7-Methoxyquinazoline;4-chloro-7-Methoxyquinazolin-6-ol
• CAS NO: 574745-97-4
• Molecular Formula: C₉H₇ClN₂O₂
• Molecular Weight: 210.61708
• Mol File: 574745-97-4.mol
• Article Data: 19

Chemical Properties

• Boiling Point: 355.8±37.0 °C(Predicted)
• Appearance: /
• Density: 1.458±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 7.55±0.40(Predicted)
• CAS DataBase Reference: 4-Chloro-6-hydroxy-7-meth...(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloro-6-hydroxy-7-meth...(574745-97-4)
• EPA Substance Registry System: 4-Chloro-6-hydroxy-7-meth...(574745-97-4)

Safety Data

• Hazardous Substances Data: 574745-97-4(Hazardous Substances Data)

Usage

General Description

4-Chloro-6-hydroxy-7-methoxyquinazoline is a chemical compound with the molecular formula C9H7ClN2O3. It is a quinazoline derivative with a chlorine atom and a methoxy group attached to the ring structure. 4-Chloro-6-hydroxy-7-meth... is a white to off-white crystalline powder that is used in the synthesis of pharmaceuticals and agrochemicals. It has demonstrated potential biological and pharmacological activities, including antiproliferative and anti-inflammatory properties. This chemical has also been studied for its potential use as a therapeutic agent in the treatment of various diseases.

Upstream product

• 230955-75-6 6-acetoxy-4-chloro-7-methoxyquinazoline 

Downstream Products

• 692059-41-9 6-(3-chloropropoxy)-4-chloro-7-methoxyquinazoline 
• 1429757-65-2 4-((3,4-dichloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-ol 
• 1626387-80-1 (R)-4-((3-chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl-2,4-dimethylpiperazinyl-1-carboxylic acid ester 
• 286371-65-1 6-(benzyloxy)-4-chloro-7-methoxyquinazoline 
• 1092364-02-7 1-((3S)-3-(4-(3-chloro-2,4-difluorophenylamino)-7-methoxyquinazolin-6-yloxy)pyrrolidin-1-yl)pro-2-pen-1-one 
• 1092365-53-1 N-(3-chloro-2,4-difluorophenyl)-7-methoxy-6-((3S)-pyrrolidin-3-yloxy)quinazolin-4-amine 
• 184475-35-2 gefitinib 

Relevant articles and documents

Preparation method of lung cancer drug AZD3759

The present invention provides a method for preparing a lung cancer drug AZD3759. Using compounds of formula VIII and compounds of formula V. as raw materials, after hydrolysis reaction, condensation reaction, ammonization reaction, acidolysis reaction, methylation reaction, compound of formula I AZD3759 was obtained. The method has a novel route, simple response, environmental friendliness and high yield, which is suitable for industrial large-scale production.

Preparation method of tyrosine kinase inhibitor AZD3759

The invention provides a preparation method of a tyrosine kinase inhibitor AZD3759, and relates to the field of medicinal chemistry. The preparation method comprises the following steps: by taking 3,4-dihydro-7-methoxy-4-oxoquinazoline-6-alcohol acetate as a raw material, carrying out a chlorination reaction and a hydrolysis reaction to obtain 4-chloro-7-methoxyquinazoline-6-alcohol (a compound 3); taking (R)-(-)-2-methylpiperazine as a raw material, and obtaining (R)-4-chlorocarbonyl-3-tert-butyl formate (compound 6) through a nucleophilic addition-elimination reaction and a chloroformylation reaction; carrying out an esterification reaction on the compound 3 and the compound 6 to obtain a compound 7; carrying out a Boc removal reaction and a methylation reaction on the compound 7 to obtain a compound 9; and carrying out alkylation reaction on the compound 9 and 2-fluoro-3-chloroaniline to obtain AZD3759. The method has the advantages of cheap and accessible raw materials and lower cost; sodium cyanoborohydride is not used in the reaction process, so that the method is more environment-friendly and is beneficial to industrial large-scale production.

Synthesis and biological evaluation of novel quinazoline-4-piperidinesulfamide derivatives as inhibitors of NPP1

The ecto-nucleotide pyrophosphatase/phosphodiesterase-1 (NPP1) was recently shown to promote mineralization of the aortic valve, hence, its inhibition represents a significant target. A quinazoline-4-piperidine sulfamide compound (QPS1) has been described as a specific and non-competitive inhibitor of NPP1. We report herein the synthesis and in vitro inhibition studies of novel quinazoline-4-piperidine sulfamide analogues using QPS1 as the lead compound. Of the 26 derivatives prepared, four compounds were found to have Ki 105 nM against human NPP1.